Top Health Tech Companies in Melbourne (50)
For more than two decades, Imprivata has been redefining how life- and mission-critical industries secure and manage digital identities. We empower healthcare and enterprise organizations to enable fast, compliant, and secure access to technology—allowing clinicians and staff to stay focused on what matters most: patient care and operational excellence. Our digital identity platform is purpose-built for complex environments where every second...
Imprivata's Top Stability & Growth Strengths
Strong Revenue Growth: Top line is described as expanding steadily in recent years, with continued growth expected. Separate reporting cites roughly $500 million in annual revenue and rapid momentum, even as exact figures vary.
Healthy Cash Flow: Cash generation has improved enough for a late‑2025 credit rating upgrade, with projections to produce over $100 million in free cash flow within the next 12–24 months. Leverage is expected to trend down alongside strong margins.
Customer Loyalty & Retention: Retention is characterized as consistently high with net expansion of spend, signaling durable relationships and effective cross‑sell within the installed base. A sizable customer count (over 4,000 organizations) supports stickiness across regions.
InterSystems builds the software that makes complex systems work—reliably, securely, and at scale. For more than 45 years, we’ve been the information engine behind some of the world’s most mission-critical applications in healthcare, government, and business. Our data management, integration, and analytics technologies help organizations connect disparate systems, turn data into insight, and deliver better outcomes. From enabling interoperable healthcare and...
InterSystems's Top Stability & Growth Strengths
Resilient & Sustainable Growth: Growth is described as measured and predictable, with signals such as modest headcount expansion, sustained operating scale, and continued momentum rather than volatility.
Innovation-Driven Growth: Recent major releases across IRIS/IRIS for Health/Health Connect and new AI-focused offerings indicate ongoing R&D velocity that broadens capabilities and use cases.
Strong Market Position & Advantage: Repeated industry accolades for Shared Care Records/HIE and regional acute EHRs in 2026 point to durable competitive standing in core healthcare markets.
Sagility is a U.S.-based, tech-enabled healthcare business process management company that supports payers, providers, and their partners to deliver best-in-class operations, enhance the member and provider experience, improve the quality of care and promote health equity all while delivering cost-effective healthcare financial and clinical outcomes. Sagility Technologies uses a holistic consulting approach to identify the root causes of healthcare payer and...
Sagility's Top Stability & Growth Strengths
Strong Revenue Growth: Recent quarters show accelerated top-line expansion with management increasing full-year growth guidance. Momentum reflects both organic gains and contributions from recent acquisitions.
Profitability: Operating metrics indicate healthy margins and rising earnings alongside revenue growth. Commentary highlights disciplined execution during peak demand periods while maintaining margin targets.
Innovation-Driven Growth: AI-led solutions, analytics, and automation are cited as material drivers of wins and efficiency across payer and provider workflows. New offerings and deployed AI use cases appear to be supporting scale and client expansion.
The Atmo Gas Capsule is a world first patented solution to accurately profile the gases within the gut, leading to better diagnosis and treatment of gastrointestinal disorders.
Telix is a biopharmaceutical company focused on the development and commercialisation of diagnostic and therapeutic ('theranostic') radiopharmaceuticals. Telix is headquartered in Melbourne, Australia with commercial operations in the United States, Europe (Belgium and Switzerland) and Japan. Telix is developing a portfolio of radiopharmaceutical products that aims to address significant unmet medical need in oncology and rare diseases. Telix is listed...
Mable is a health-tech platform where people looking for disability and aged care support connect with independent support workers in their community. As one of Australia’s fastest-growing scale-ups, we think big to spearhead change in our sector. We're passionate about inclusivity and giving choice and control back to those who need it. Mable launched in 2014 when co-founder Peter Scutt...
Healthcare Australia (HCA) is Australia’s largest diversified healthcare provider, operating nationwide across all sectors of health including primary health care, and acute care. We connect healthcare professionals, organisations, and people to provide end-to-end healthcare solutions. By filling the healthcare skills gap, we ensure Australians always have the support they need—making us Australia's #1 healthcare solutions provider. We're highly experienced: With over 50...
PKG Health believes every person with a neurological condition deserves to live their best life every day. We leverage the world’s largest body of clinical evidence in neurology, to create and deliver precision medicine by accelerating the research, approval and adoption of treatments. Its lead product, the Parkinson's KinetiGraph®(PKG® or Personal KinetiGraph® in the US), has been developed by neurologists...
Halaxy makes healthcare better all over the world. Halaxy is a platform for patients, practitioners and people everywhere, and provides: 1. Practice management software (EMR, billing and scheduling) for any practitioner of any profession in any practice anywhere in the world; 2. Searchable practitioner directories covering 50% of the English speaking world enabling people to find the right practitioner for...
ProPharma is the premier Research Consulting Organization (RCO), delivering fully customizable consulting solutions to empower biotech, med device, and pharmaceutical organizations of all sizes to advance scientific breakthroughs confidently and introduce new therapies. With over 20 years of expertise in regulatory sciences, clinical research solutions, quality & compliance, pharmacovigilance, medical information, and R&D technology, ProPharma partners with clients across the...
Smileyscope is a multi-award winning digital therapeutics company with proprietary technology that reframes medical procedures using choreographed virtual-reality (VR) experiences to help reduce patient pain and anxiety, and improve the overall patient experience. Our vision is to expand the frontiers of patient-centered care, improving the moments that matter most. Smileyscope VR is the first regulatory body approved VR product for...
HotDoc is Australia's largest and most trusted patient engagement platform. We take pride in helping over 21,000 practitioners connect with more than 9 million patients. The HotDoc platform includes: online bookings, recalls, reminders, check-in, place in queue, online processing of repeat prescription requests, and Inform (a tool designed to encourage patients to take a more proactive interest in preventative health...
Natural MedTech is manufacturing psychedelic medicines to unlock neurologic potential. We are building Australia’s leading pure-play psychedelic business, with differentiated IP, an experienced team, and a self-funding growth profile.
Bupa's purpose is helping people live longer, healthier, happier lives and making a better world. We are an international healthcare company serving over 38 million customers worldwide. With no shareholders, we reinvest profits into providing more and better healthcare for the benefit of current and future customers. We directly employ around 85,000 people, principally in the UK, Australia, Spain, Chile, Poland, New...
Bupa's Top Stability & Growth Strengths
Strong Revenue Growth: Group results show double‑digit revenue and underlying profit growth in 2024, with customers rising sharply. 2025 materials indicate continued revenue and profit increases alongside a larger customer base, with growth remaining solid even excluding first‑time consolidation effects.
Strong Market Position & Advantage: Independent market analysis places Bupa as the UK PMI leader within a concentrated 'big four', and official statistics show it as the largest fund in Australian private health insurance. Bupa Global is viewed as a tier‑one IPMI provider, and the insurer‑plus‑provider model strengthens competitive positioning across multiple regions.
Market Expansion: Company updates highlight ongoing expansion of clinics, dental centres, hospitals and digital health (Blua), with dozens of new sites opened in 2024 and further additions in 2025. Portfolio moves such as consolidating Niva Bupa in India and adding UK provision assets broaden reach into fast‑growing markets and channels.
Integral Diagnostics is a leading provider of medical imaging services across Australia and New Zealand, offering a comprehensive range of diagnostic modalities including MRI, CT, X-ray, and ultrasound.
MedHealth is a purpose-built collection of industry-leading health, medical, and employment brands that leverage diverse capabilities to deliver optimal health and employment outcomes for the people and communities they support.
Doctify is a high-growth HealthTech company revolutionising the global healthcare market. Having expanded into 6 markets with an ambitious growth plan over the coming year. Doctify has developed a first-of-its-kind healthcare-specific patient feedback and review product allowing healthcare professionals to drive improvements in patient care on a daily basis. Our SaaS product allows healthcare providers to collect and digitize patient feedback and...
Mayne Pharma is an ASX-listed specialty pharmaceutical Company (ASX: MYX) focused on commercializing novel and generic pharmaceuticals. We offer patients better, safe and more accessible medicines. Mayne Pharma has a 40-year track record of innovation and success in developing oral drug delivery systems. These technologies have been successfully commercialized in numerous products that continue to be marketed around the world....
Mesoblast (ASX:MSB; Nasdaq:MESO) is developing and commercializing allogeneic cellular medicines to treat serious and life-threatening inflammatory diseases with significant, unmet medical needs. The Company's Phase 3 off-the-shelf mesenchymal lineage cell product candidates are: • RYONCIL™ (remestemcel-L) for steroid-refractory acute graft versus host disease (acute GVHD) • Remestemcel-L for moderate to severe acute respiratory distress syndrome (ARDS) due to COVID-19 infection • REVASCOR® for advanced...
Ansell is a world leader in providing superior health and safety protection solutions that enhance human well-being. The world’s need for better protection never stops, so Ansell is constantly researching, developing and investing to manufacture and distribute cutting edge product innovation and technology, marketed under well-known brands that customers trust. Operating in two main business segments, Industrial and Healthcare, Ansell is...
